Advanced Vancomycin Calculator

1. Scope and clinical target

This tool supports clinician review of adult intermittent-infusion vancomycin regimens. It offers conventional first-order pharmacokinetics and five Bayesian population priors. The calculation method, population suitability, dose record, sampling conditions, and warnings must be reviewed together. Computational quality checks do not establish external clinical validation of this implementation.

The MIC field changes the reported AUC/MIC ratio; it does not multiply the exposure target or the maintenance dose. An AUC above 600 triggers an exposure warning. The target boundary is not a guarantee about an individual patient's toxicity risk.

Pregnancy, pediatric dosing, intermittent hemodialysis, SLED, peritoneal dialysis, and temporary mechanical circulatory support (including ECMO and temporary VAD) are outside this implementation. Non-CRRT estimates require reasonably stable renal function. The retained CRRT pathway does not model interruptions or changing settings; known downtime, changing renal conditions, or an inconsistent dose history prevents calculation when the relevant exclusion is present.

2. Choose a workflow

First select the calculation method, then the workflow that matches the information actually available. Selecting a steady-state workflow does not establish that steady state has been reached.

Bayesian and conventional methods

Bayesian fitting combines the selected population model with the recorded concentrations. Conventional fitting uses one-compartment finite-infusion equations. A good numerical fit alone cannot establish that the population model or dose record is correct. Published comparisons also show that AUC estimates can depend on estimation method and sampling. [10]

Automatic conventional fallback attempts an alternative only when the selected data also meet the conventional pathway's scope and timing rules. Review the displayed method after every calculation. An input-quality failure, CRRT change, or unstable renal function is not a reason to force a conventional result.

3. Enter doses and sample times

Calculate, review, and edit a case

After a successful calculation, the input form is replaced by a read-only snapshot showing the patient parameters, workflow, regimen, and concentrations used. Compare it with the intended clinical record. Edit clinical inputs restores the form and removes the earlier result. Calculate again after revising the clinical inputs.

The custom maintenance fields are a draft. Calculate custom regimen evaluates them on screen. Calculate displayed regimen and download report evaluates the currently displayed fields and exports that newly calculated result. A blank or invalid custom field prevents export. Earlier evaluated custom results identify the exact regimen they describe.

Sample times are elapsed hours from the start of the most recent recorded infusion. Infusion duration is the actual time the dose ran. The number of doses reconstructs identical doses at the stated interval; it is not an arbitrary administration timeline.

A first-dose history begins at elapsed hour 0. With three regular doses every 12 hours, the recorded starts are hours 0, 12, and 24. A sample three hours after the latest start has a collection time of 3 hours in the form and elapsed treatment time of 27 hours in the reconstructed record.

Two samples are preferred for Bayesian AUC monitoring, including a postinfusion sample at 1-2 hours after completion and a trough. A single trough may suffice in selected patients. Bayesian assessment can precede steady state; conventional two-level assessment requires suitable concentrations near steady state. [1]

The retained first-dose option provides a specific early-therapy workflow. For a course containing a different loading dose, held or additional doses, variable intervals, stopped infusions, or residual drug from an earlier course, a regular dose-count reconstruction can be inaccurate. Do not adjust the count or interval to disguise an irregular history. Reconcile the record and use a pathway that represents the actual administrations.

Data-quality questions

Confirm whether the sample came from an infusion line, all doses are accurately represented, infusion duration was actual, renal function changed, or CRRT settings changed. An unknown answer remains an unresolved uncertainty. Known contradictions can block calculation rather than be routed to another equation.

Duplicate or nearly simultaneous levels provide little additional elimination information. The software includes a 15-minute spacing safeguard; this is a computational screening rule, not a clinical statement that any larger spacing is adequate. Distribution, laboratory variability, model suitability, and the interval between informative samples still require review.

4. Select a population model

Automatic selection uses CRRT first, then BMI at least 30, then critical illness, then the general-adult prior. Hematologic malignancy can prompt consideration of the manually selected Belabbas prior. The automatic choice is a starting point for clinical review.

Obesity, critical illness, and hematologic malignancy may overlap. Use the optional comparison only for eligible priors and inspect its limitations. A fixed-parameter, two-compartment model does not automatically describe changing clearance.

5. Read the renal estimates

The renal-transparency display separates the uncapped calculation from the covariate actually used. It shows the weight basis, units, retained limits, and reason for the difference. These limits describe the calculator's implementation; they are not universal physiologic limits.

The manual CrCl override is for the conventional pathway. It does not override the renal covariate in every Bayesian model. Confirm the active method and its displayed covariate before interpreting an override.

Vancomycin CL is drug clearance in L/h. Cockcroft-Gault CrCl is a renal estimate in mL/min. Their numbers are not expected to be equal. Differences call for review of units, covariates, measured levels, and clinical circumstances.

6. Interpret uncertainty and information level

The information label records how many concentrations informed the calculation. It does not grade the quality of those samples or certify accuracy.

Population prior only: No concentration updates the model. Any displayed prior spread describes the assumed population variability; it is separate from a fitted posterior range.

One-level Bayesian estimate: CL is fitted while central volume and other distribution parameters remain at their model values. A narrow CL range can still depend strongly on those fixed assumptions.

Two-level Bayesian estimate: CL and central volume are fitted when supported by the retained prior. Tsai retains central volume. Sparse or poorly separated observations may contribute limited information even when two values are entered.

The local log-scale approximation uses a multiplier of 1.96. If reliable local curvature cannot be obtained, convergence fails, or a parameter reaches a limiting boundary, the range may be unavailable. A range whose endpoints cross fitted-parameter or physical PK limits is withheld rather than silently shortened. An unavailable range is not zero uncertainty. The reason should be reviewed with the estimate.

Clearance and AUC ranges are linked

For a fixed regular regimen under linear, constant-clearance steady-state assumptions:

With daily dose in mg and CL in L/h, AUCss24 is in mg*h/L. For example, a hypothetical 2,000 mg daily dose with CL from 3 to 5 L/h yields an AUC range from 400 to approximately 667 mg*h/L. This arithmetic example is not a dosing recommendation.

The calculation report identifies the regimen used for the range. If no current or clinician-selected fixed regimen is available, a fitted AUC range may be unavailable. A dose recalculated at every CL value to force the same target would conceal exposure uncertainty.

7. Review and compare regimens

Current, exact-target, and clinician-selected regimens

The current-regimen estimate evaluates the dose and interval entered. The exact-target result calculates the mathematical, unrounded dose corresponding to the selected exposure and estimated CL. A clinician-selected regimen lets you enter a practical dose, interval, and infusion duration and review the resulting AUC, peak, trough, and infusion rate. Review each result's label; they answer different questions.

Candidate range and ranking: A candidate inside AUC 400-600 mg*h/L ranks ahead of an outside-range candidate. Within that group, ranking also considers the selected target, interval preference, and daily dose. The first row is a candidate for clinical review, not a guarantee of the closest mathematical AUC or an automatically authorized order. AUC range status is displayed explicitly.

Choose infusion times before calculating

The 10 mg/min policy remains the default: at least 60 minutes, no faster than 10 mg/min, rounded upward to the next 15 minutes. For 1,000 mg, the generated duration is 1.75 hours. The alternative dose-based infusion times use the supplied table below. Select 2.5 or 3 hours for doses above 2,000 mg before calculating.

Each cutoff includes the stated upper dose; an exact mathematical dose just above a cutoff moves into the next band before display rounding. The selected policy applies to generated future regimens and the exact-target reference. It does not rewrite actual administration history or a clinician-entered custom duration. Snapshots and downloaded reports record the selected policy and the high-dose choice.

Read the infusion equations and examples and the complete conventional equations and pharmacokinetic background.

Loading reference: The obesity-specific 20-25 mg/kg actual-weight reference takes precedence over the broader non-obese critical-illness reference, with the retained 3000 mg cap. The displayed loading amount is a reference for clinical review. [1]

The average steady-state concentration summarizes the area under the concentration-time curve divided by 24 hours. It is not a trough or a peak and is not a replacement for the AUC target. See the exposure equations.

An unrounded mathematical dose is not a ready-to-administer order. Reconcile the practical regimen with preparation, infusion, monitoring, and local prescribing requirements. Changing infusion duration changes predicted peak and trough; it does not change steady-state AUC when dose, interval, and CL are fixed.

AUCss24 is not automatically the first-day AUC. Loading doses, accumulation, earlier drug exposure, and later clinical changes can alter exposure over a particular 24-hour window. In the first-dose conventional workflow, AUC0-infinity equals the single dose divided by CL; a separately labeled first-dose AUC0-24 represents a different quantity. The linear-up/log-down value is an approximation and a cross-check, not an independent clinical validation. [9]

Optional model sensitivity

The sensitivity table holds the comparison regimen constant and evaluates it using other eligible priors with the same patient data and concentrations. It reports CL, AUC, differences from the selected prior, and fit or eligibility limitations. It does not replace the selected prior or generate several competing prescriptions.

Different priors may be reasonable candidates in overlapping populations. A 2026 study of 90,295 patients reported more than 20% differences in a priori AUC for 7.7% when comparing modified Goti with capped Thomson. Its observational design and commercial-platform setting do not validate the models or comparisons in this calculator. [7]

Inspect the named comparison regimen first. In a pre-dose workflow, enter a clinician-selected regimen if a fixed comparison is needed. Avoid choosing whichever prior gives the most convenient dose. Large disagreement should prompt input review, assessment of applicability, and additional informative data when appropriate.

8. Respond to poor fit or unexpected exposure

Review the observed-versus-predicted concentrations, residuals, convergence, boundaries, information level, and all warnings. A concentration can fit a model well while the history or population choice remains wrong.

1. Reconcile administrations. Verify dose amount, actual start and finish times, all preceding doses, and any held, late, partial, or extra administration.
2. Verify collection. Use the actual specimen time; investigate infusion-line sampling, collection during infusion, or a time recorded before any represented dose.
3. Review changing physiology and treatment. Assess renal trajectory, fluid status, and CRRT interruptions or changed settings. These changes can invalidate the current fixed-parameter calculation.
4. Assess whether the sample pair is informative. Duplicate, closely timed, or distribution-phase samples cannot be repaired by relabeling them.
5. Reassess the model. Consider another eligible prior or another informative concentration under the institutional monitoring plan.
6. Choose an appropriate alternative. Use conventional two-level estimation only if its assumptions hold; otherwise follow the specialist pathway.

Reassess promptly after an unexpected concentration, meaningful renal change, dose change, or CRRT change. A new dose calculation cannot itself resolve unsupported changing conditions. Use clinical judgment and institutional monitoring policy rather than a universal three-or-five-day interval.

9. Save a calculation report

The downloadable calculation report supports review of the method, model, original and normalized inputs, dose reconstruction, concentration times, renal covariates, PK estimates, regimen comparisons, warnings, uncertainty, and fit diagnostics. Verify that the report corresponds to the intended calculation before adding it to any clinical workflow.

Dose and sample events use elapsed time. This form does not collect absolute clinical dose or collection dates. The report therefore shows elapsed infusion starts, stops, and collection times. A report-generation timestamp describes when the report was created; it is not a patient's administration date. Synthetic timing anchors used internally are not exported as patient-event dates.

The form does not request a patient name, medical-record number, or birth date. The application does not save entered clinical inputs. The PHP versions process submitted inputs on the server; the JavaScript version performs the calculation in the browser. A downloaded report is saved in the destination selected by the user. Retention and handling of that copy follow the user's clinical workflow. This describes the application, not an absolute guarantee about independent hosting, logging, browser, or download retention.

10. Health-system implementation and competency

Before adopting this calculator in an institutional workflow, designate a clinical owner and agree on inclusion criteria, escalation pathways, dose and concentration documentation, review responsibilities, and downtime procedures. The DoseMeRx webinar describes practical experience with training, communication, and ongoing program review; it is workflow evidence, not an equation reference. [8]

Use representative, deidentified cases to compare the complete implementation with an independently reviewed method. Include stable general adults, obesity with ICU overlap, hematologic malignancy, one- and two-level cases, prior-only estimates, manual conventional CrCl, and supported CRRT cases. Include cases that must be rejected, such as inconsistent history, changing CRRT conditions, and incompatible timing.

Staff should be able to explain the active method, fixed versus fitted parameters, elapsed-time convention, renal limits, custom-regimen results, MIC behavior, uncertainty limitations, and when to stop calculation and seek review. Handoffs should identify unresolved inputs and the reason for the next assessment.

Primary-source verification limits: The Roberts, Zhang, and Tsai structural tables were available for review. Detailed Goti and Belabbas tables and the Goti 2019 erratum were not obtained, so complete original-source transcription cannot be claimed. Roberts uses a renal-estimate proxy and an approximate residual likelihood; Zhang has published weight-center and CKD-EPI supplement discrepancies. The retained decisions are documented in the accompanying clinical-source review. Resolve these items and evaluate the exact implementation independently before unrestricted adoption.

Computational QA is not external clinical validation. Matching PHP and JavaScript outputs, checking algebraic identities, and preserving golden-case results support reproducibility. They do not establish prospective target attainment, calibrated patient-level uncertainty, clinical outcomes, or equivalence to another dosing platform. Assess those questions separately before institutional adoption.

Entering numbers and correcting errors

Use a decimal point, for example 1.5. Do not enter commas, thousands separators, units, or other text in a numeric entry. Select the appropriate units beside height, weight, and serum creatinine. Values such as 1,5 and 1mg remain visible and are rejected; the calculator does not guess the intended value.

An invalid field has a red border, a pale red background, and a specific explanation beside it. The error summary links to the affected fields. Missing required entries, numbers outside the supported range, fractional administered-dose counts, and incompatible timing must be corrected before calculation. Required markers follow the selected workflow. A blank required field is not zero.

Interactive editions update simple entry errors as you correct them. Clinical errors that depend on calculation retain a reminder to calculate again. In pure PHP, correct the entries and submit again for updated feedback. Invalid custom-regimen drafts cannot generate a new calculation report.

Application release 1.8 retains strict entry validation and adds a choice of generated-regimen infusion times. Results and reports suppress insignificant decimal zeros. Editing preserves the entered text, and formatting does not change the values used by the calculation.

11. References

Sources reviewed October 16, 2026. The IDSA page continues to identify the 2020 joint monitoring guideline as current. A reference supports its stated population, methods, or workflow; it does not constitute endorsement or validation of this implementation.

1. Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review. American Journal of Health-System Pharmacy. 2020;77(11):835-864. DOI: 10.1093/ajhp/zxaa036. PMID: 32191793. IDSA guideline. ASHP full guideline.
2. Goti V, Chaturvedula A, Fossler MJ, Mok S, Jacob JT. Hospitalized patients with and without hemodialysis have markedly different vancomycin pharmacokinetics: a population pharmacokinetic model-based analysis. Therapeutic Drug Monitoring. 2018;40(2):212-221. DOI: 10.1097/FTD.0000000000000490. PubMed 29470227.
3. Roberts JA, Taccone FS, Udy AA, Vincent JL, Jacobs F, Lipman J. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrobial Agents and Chemotherapy. 2011;55(6):2704-2709. DOI: 10.1128/AAC.01708-10. PubMed 21402850.
4. Zhang T, et al. How to dose vancomycin in overweight and obese patients with varying renal (dys)function in the novel era of AUC 400-600 mg*h/L-targeted dosing. Clinical Pharmacokinetics. Published online 2023. DOI: 10.1007/s40262-023-01324-5. Full article. PubMed 37971650.
5. Tsai MT, et al. Population pharmacokinetics of vancomycin in intensive care patients with the time-varying status of temporary mechanical circulatory support or continuous renal replacement therapy. Infectious Diseases and Therapy. 2024. DOI: 10.1007/s40121-024-01071-5. Full article. PubMed 39541003.
6. Belabbas T, et al. Population pharmacokinetic model and dosing optimization of vancomycin in hematologic malignancies with neutropenia and augmented renal clearance. Journal of Infection and Chemotherapy. 2023;29(4):391-400. DOI: 10.1016/j.jiac.2023.01.010. PubMed 36682608.
7. Tong DMH, Brooks JT, Keizer RJ, Hughes JH. Vancomycin target attainment improved following population pharmacokinetic model switch: a large-scale quasi-experimental study of precision dosing. JAC-Antimicrobial Resistance. 2026;8(1):dlag016. DOI: 10.1093/jacamr/dlag016. Full article. PubMed 41710913. Observational study; authors disclosed employment and stock ownership in InsightRX.
8. DoseMeRx. Do's and Don'ts of Bayesian Dosing: Webinar Recording. Webinar and implementation Q&A. Accessed October 16, 2026. Vendor-hosted implementation discussion; no DOI.
9. Sujjavorakul K, Katip W, Kerr SJ, Wacharachaisurapol N, Puthanakit T. Predicting the area under the plasma concentration-time curve (AUC) for first dose vancomycin using first-order pharmacokinetic equations. Antibiotics. 2023;12(4):630. DOI: 10.3390/antibiotics12040630. PubMed 37106993. Cited to explain the distinction between the retained legacy first-dose method and later distribution-compensated equations.
10. Olney KB, Wallace KL, Mynatt RP, et al. Comparison of Bayesian-derived and first-order analytic equations for calculation of vancomycin area under the curve. Pharmacotherapy. 2022;42(4):284-291. DOI: 10.1002/phar.2670. PubMed 35134264.
11. Hospira. Vancomycin hydrochloride powder for IV solution. DailyMed label updated April 1, 2026. Adult dosage and infusion administration. Reviewed product-specific label. Confirm labeling for the actual product used.